Our laboratory provides state-of-the-art testing for preclinical ocular toxicity. It is vitally important to test drugs early on for ocular toxicity before major investment has been made in the development process, as this could have serious repercussions for patients and researchers if left undetected.
Pharmacodynamic and Pharmacokinetic Assessment
Test your drug for its effects on the eye
Welcome to The Steinbeis-Transferzentrum!
Preclinical Ocular Toxicity
Preclinical ocular toxicity
About OcuTox
STZ OcuTox offers unique expertise and services relating to all aspects of preclinical testing of events in the eye. Read more about our profile:
Prof. Dr. Ulrich Schraermeyer
Director of STZ OcuTox
As a scientist and internationally acknowledged expert he is specialized in the pathology of the retinal pigment epithelium, a key cell layer for pathogenic events in AMD. The purpose of his unit is the discovery of candidates for ophthalmological drug development and also the support of pharmaceutical entities in toxicological and efficacy studies with respect to events in the eye.
+49-70 71-2 98 07 15
info@ocutox.com
Prof. Dr. Ulrich Schraermeyer
Director of STZ OcuTox
Dr. Schraermeyer also heads the Section of Experimental Vitroretinal Surgery at the Centre for Ophthalmology, University Eye Hospital in Tübingen.
As a co-founder of the biotechnology companies Cevec in 2003, and katairo in 2011 he has gathered first hand industrial experience.
Dr. Schraermeyer holds a degree in cellular biology and a PhD from the University of Düsseldorf.
+49-70 71-2 98 07 15
info@ocutox.com
OcuTox Your Expert for
Toxicology Pharmacodynamics assessment
Services We Provide
WHY WORK WITH US
Application
we always think about human application when we are doing experiments with animals
Experience
We have great experience with drugs and other factors which worsen or rescue the function of eyes
Histological changes
Different ways
We know the different ways of thinking of clinicians, patients, scientists, regulatory board members, investors and pharmaceutical industrial partners and keep that in mind during a drug development process
